The therapeutic efficacy of propranolol in children with recurrent primary epistaxis

We hypothesized that some characteristics of beta-blockers, including negative inotropic, peripheral vasoconstrictor, and antiangiogenic effects, might be potentially useful in treating children with epistaxis. From June 2010 to March 2012, a total of seven children with recurrent primary epistaxis...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjelakovic, Bojko, Bojanovic, Mila, Lukic, Stevo, Saranac, Ljiljana, Vukomanovic, Vladislav, Prijic, Sergej, Zivkovic, Nikola, Randjelovic, Dusica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3588605/
https://www.ncbi.nlm.nih.gov/pubmed/23467483
http://dx.doi.org/10.2147/DDDT.S41756
_version_ 1782261594811531264
author Bjelakovic, Bojko
Bojanovic, Mila
Lukic, Stevo
Saranac, Ljiljana
Vukomanovic, Vladislav
Prijic, Sergej
Zivkovic, Nikola
Randjelovic, Dusica
author_facet Bjelakovic, Bojko
Bojanovic, Mila
Lukic, Stevo
Saranac, Ljiljana
Vukomanovic, Vladislav
Prijic, Sergej
Zivkovic, Nikola
Randjelovic, Dusica
author_sort Bjelakovic, Bojko
collection PubMed
description We hypothesized that some characteristics of beta-blockers, including negative inotropic, peripheral vasoconstrictor, and antiangiogenic effects, might be potentially useful in treating children with epistaxis. From June 2010 to March 2012, a total of seven children with recurrent primary epistaxis resistant to conventional management were observed at our institution. An overall effectiveness of propranolol was noted in all seven children when given a dose of 1.5–2 mg/kg/day (divided into three doses) as a second line therapy for terminating epistaxis. Based on our first experience, we believe that propranolol could be a favorable treatment option for patients with primary epistaxis.
format Online
Article
Text
id pubmed-3588605
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-35886052013-03-06 The therapeutic efficacy of propranolol in children with recurrent primary epistaxis Bjelakovic, Bojko Bojanovic, Mila Lukic, Stevo Saranac, Ljiljana Vukomanovic, Vladislav Prijic, Sergej Zivkovic, Nikola Randjelovic, Dusica Drug Des Devel Ther Original Research We hypothesized that some characteristics of beta-blockers, including negative inotropic, peripheral vasoconstrictor, and antiangiogenic effects, might be potentially useful in treating children with epistaxis. From June 2010 to March 2012, a total of seven children with recurrent primary epistaxis resistant to conventional management were observed at our institution. An overall effectiveness of propranolol was noted in all seven children when given a dose of 1.5–2 mg/kg/day (divided into three doses) as a second line therapy for terminating epistaxis. Based on our first experience, we believe that propranolol could be a favorable treatment option for patients with primary epistaxis. Dove Medical Press 2013-03-01 /pmc/articles/PMC3588605/ /pubmed/23467483 http://dx.doi.org/10.2147/DDDT.S41756 Text en © 2013 Bjelakovic et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Bjelakovic, Bojko
Bojanovic, Mila
Lukic, Stevo
Saranac, Ljiljana
Vukomanovic, Vladislav
Prijic, Sergej
Zivkovic, Nikola
Randjelovic, Dusica
The therapeutic efficacy of propranolol in children with recurrent primary epistaxis
title The therapeutic efficacy of propranolol in children with recurrent primary epistaxis
title_full The therapeutic efficacy of propranolol in children with recurrent primary epistaxis
title_fullStr The therapeutic efficacy of propranolol in children with recurrent primary epistaxis
title_full_unstemmed The therapeutic efficacy of propranolol in children with recurrent primary epistaxis
title_short The therapeutic efficacy of propranolol in children with recurrent primary epistaxis
title_sort therapeutic efficacy of propranolol in children with recurrent primary epistaxis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3588605/
https://www.ncbi.nlm.nih.gov/pubmed/23467483
http://dx.doi.org/10.2147/DDDT.S41756
work_keys_str_mv AT bjelakovicbojko thetherapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT bojanovicmila thetherapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT lukicstevo thetherapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT saranacljiljana thetherapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT vukomanovicvladislav thetherapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT prijicsergej thetherapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT zivkovicnikola thetherapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT randjelovicdusica thetherapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT bjelakovicbojko therapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT bojanovicmila therapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT lukicstevo therapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT saranacljiljana therapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT vukomanovicvladislav therapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT prijicsergej therapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT zivkovicnikola therapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis
AT randjelovicdusica therapeuticefficacyofpropranololinchildrenwithrecurrentprimaryepistaxis

Ejemplares similares